Table of Content

1. Global Opioid-Induced Constipation Treatment Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Global Opioid-Induced Constipation Treatment Market -Market Definition and Overview
3. Global Opioid-Induced Constipation Treatment Market – Executive Summary
3.1. Market Snippet By Drug Class
3.2. Market snippet By Route of administration
3.3. Market Snippet By Distribution Channel
3.4. Market Snippet by Region
4. Global Opioid-Induced Constipation Treatment Market-Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The rise in the availability of effective OIC drugs
4.1.1.2. Rise in the Availability of Effective OIC Drugs Along with Growing Prevalence of Chronic Idiopathic Pains
4.1.2. Restraints:
4.1.2.1. Lack of awareness about OIC among the patients
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Global Opioid-Induced Constipation Treatment Market – Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. Global Opioid-Induced Constipation Treatment Market – COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. Global Opioid-Induced Constipation Treatment Market – By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
7.1.2. Market Attractiveness Index, By Drug Class Segment
7.2. Mu-Opioid Receptor Antagonists*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.2.3. Methylnaltrexone
7.2.4. Naloxegol
7.2.5. Naldemedine
7.2.6. Others
7.3. Chloride Channel Activators
7.3.1. Lubiprostone
7.3.2. Others

8. Global Opioid-Induced Constipation Treatment Market – By Route of administration
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
8.1.2. Market Attractiveness Index, By Route of administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Parenteral
9. Global Opioid-Induced Constipation Treatment Market – By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel Segment
9.2. Hospital Pharmacy*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Retail Pharmacy
9.4. Online Pharmacy
9.5. Other
10. Global Opioid Induced Constipation Treatment Market – By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Global Opioid Induced Constipation Treatment Market – Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
12. Global Opioid Induced Constipation Treatment Market - Company Profiles
12.1. AstraZeneca plc*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Mallinckrodt Pharmaceuticals
12.3. Bausch Heath (Salix Pharmaceuticals )
12.4. Merck & Co Inc
12.5. Shionogi & Co Ltd
12.6. GlaxoSmithKline (Theravance Biopharma Inc)
12.7. Takeda Pharmaceutical
12.8. Novartis AG (Sandoz)
12.9. Cubist Pharmaceuticals
12.10. Pfizer, Inc.
LIST NOT EXHAUSTIVE
13. Global Opioid Induced Constipation Treatment Market – DataM
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us